Drugs / vitespen
vitespen
Trials 20 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02722512 | Jul 2016 → Nov 2019 | anaplastic astrocytoma, anaplastic ependymoma, clear cell ependymoma, glioblastoma | Ann & Robert H Lurie Children's Hospital of Chicago | Terminated | No outcome recorded |
| Phase 1 | NCT02122822 | Jul 2013 → Jul 2015 | glioma | Cure&Sure Biotech Co., LTD | Completed | No outcome recorded |
| Phase 1 | NCT00003025 | Mar 1997 → Jul 2002 | pancreatic adenocarcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT02452281 | Dec 2015 → Dec 2018 | melanoma | Rabih Said | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02317471 | Nov 2014 → Dec 2017 | gastric carcinoma | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT02133079 | Mar 2012 → Nov 2016 | liver cancer, pancreatic adenocarcinoma | Cure&Sure Biotech Co., LTD | Unknown | No outcome recorded |
| Phase 1/2 | NCT00293423 | Nov 2005 → Jan 2013 | central nervous system neoplasm | University of California, San Francisco | Completed | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT03650257 | Aug 2019 → Aug 2021 | brain glioma | Cure&Sure Biotech Co., LTD | Unknown | No outcome recorded |
| Phase 2 | NCT03018288 | Sep 2017 → Dec 2022 | glioblastoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT01814813 | Jun 2013 → Apr 2017 | gliosarcoma | Alliance for Clinical Trials in Oncology | Terminated | No outcome recorded |
| Phase 2 | NCT01147536 | Jan 2010 → Jun 2012 | renal cell carcinoma | Agenus Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00905060 | Jun 2009 → Jun 2014 | brain cancer | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT00098085 | Sep 2003 → Nov 2007 | non-small cell lung carcinoma | Agenus Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00082459 | Jul 2002 → Dec 2005 | renal cell carcinoma | Agenus Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00081809 | Mar 2000 → Jun 2005 | chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma | Agenus Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00005628 | Nov 1999 → Aug 2001 | sarcoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04206254 | Dec 2019 → Aug 2022 | liver cancer | Cure&Sure Biotech Co., LTD | Unknown | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT00126178 | May 2005 → Mar 2006 | renal cell carcinoma | Agenus Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00039000 | Mar 2002 → Dec 2005 | melanoma | Agenus Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00033904 | Jun 2000 → Apr 2007 | renal cell carcinoma | Agenus Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01799161 Comparator | Dec 2014 → Apr 2018 | non-small cell lung carcinoma | Eckhard Podack | Withdrawn | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vitespen | “an autologous, tumour-derived heat-shock protein (glycoprotein 96)-peptide complex (HSPPC-96; vitespen) as adjuvant treatment in patients at high risk of recurrence after...” PMID 18602688 ↗ Jul 2008 |
| Known as | gp96 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02133079 ↗ |
| Known as | gp96-Ig Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01799161 ↗ |
| Known as | heat shock protein gp96 | “Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96” NCT02133079 ↗ |
| Known as | heat shock protein peptide complex -96 (HSPPC 96) | “heat shock protein peptide complex -96 (HSPPC 96)” NCT03018288 ↗ |
| Known as | heat-shock protein peptide complex-96 | “an autologous heat-shock protein peptide complex-96 (HSPPC-96) vaccine for patients with recurrent GBM” PMID 24335700 ↗ Dec 20132“The vaccine is called heat shock protein peptide complex 96 (HSPPC-96).” NCT01814813 ↗ “Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine” NCT02722512 ↗ |
| Known as | HSPPC-96 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01147536 ↗ |
| Known as | HSPPC-96 (Heat Shock Protein-Peptide Complex) | “HSPPC-96 (Heat Shock Protein-Peptide Complex)” NCT01147536 ↗ |
| Known as | Oncophage | “Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma” NCT00082459 ↗1“Heat Shock Protein-Peptide Complex - 96 (HSPPC-96 or Oncophage)” NCT00039000 ↗ |
| Action | Deplete | “Vaccines made from a person's cancer cells may make the body build an immune response to and kill tumor cells.” NCT00003025 ↗ |
| Modality | Vaccine | “Vaccine therapy” NCT00003025 ↗ |
| Route | Subcutaneous | “autologous tumor derived gp96 heat shock protein peptide complex (HSPPC-96) subcutaneously once a week for 4 weeks” NCT00003025 ↗ |